MedTrace Logo

AN69ST Verse PS in CBP in Septic Children

NCT05692011 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-02-17

No results posted yet for this study

Summary

In septic shock, dysregulated host responses to pathogens lead to cytokine storms that damage host tissues and organs, further contributing to the development of organ dysfunction and increased mortality. For sepsis, blood purification can remove inflammatory factors in sepsis by filtration or adsorption, so as to achieve the purpose of reducing inflammatory mediators in the body. However, there are few prospective randomized controlled studies in children. Therefore, this study intends to compare the efficacy and prognosis of different membrane on children with sepsis through a perspective cohort study, so as to provide a corresponding basis for the treatment of children with sepsis blood purification.

Conditions

Interventions

DEVICE

blood purification(PS)

After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with PS membrane, 24 hours per day, for 3 consecutive days

DEVICE

blood purification(AN69ST)

After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with AN69ST membrane, 24 hours per day, for 3 consecutive days

Sponsors & Collaborators

  • West China Second University Hospital

    collaborator OTHER

  • Children's Hospital of Chongqing Medical University

    collaborator OTHER

  • First Affiliated Hospital of Xinjiang Medical University

    collaborator OTHER

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • Children's Hospital of Soochow University

    collaborator OTHER

  • Southern Medical University, China

    collaborator OTHER

  • Children's Hospital of Fudan University

    lead OTHER

Eligibility

Min Age
29 Days
Max Age
28 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05692011 on ClinicalTrials.gov